GlassScriptPhysician profile
Mo Keovongsa
NPI 1710157300
$6,485.44
in general payments reported to CMS, 2019-2025
31 companies · $2,425 in 2025
The $2,425 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.58 · 2023: $116 · 2024: $3,920 · 2025: $2,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,392 · Education: $69.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,391.57 |
| Education | $69.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.40 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $739.05 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $593.82 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $517.86 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $496.53 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $486.04 | 2024-2025 | Vemlidy |
| Pfizer INC. | $442.95 | 2024-2025 | |
| Qol Medical, LLC | $347.10 | 2024-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $270.91 | 2024 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $201.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $188.86 | 2024-2025 | |
| Ardelyx, INC. | $179.10 | 2023-2025 | Ibsrela |
| Celgene Corporation | $163.95 | 2024 | Zeposia |
| Boston Scientific Corporation | $147.57 | 2024 | Captivator II |
| Celltrion USA INC. | $97.85 | 2024-2025 | Zymfentra, Yuflyma, Vegzelma |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $92.97 | 2024-2025 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $89.63 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $83.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $68.64 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $66.37 | 2024-2025 | |
| Lilly USA, LLC | $55.84 | 2024-2025 | Omvoh, Zepbound |
| Neuraxis, INC. | $54.32 | 2025 | |
| Braintree Laboratories, INC. | $40.48 | 2024 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $34.52 | 2024 | Idacio |
| Aimmune Therapeutics, INC. | $31.66 | 2024-2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2024 | Cyltezo |
| Exact Sciences Corporation | $22.98 | 2025 | The Cologuard Plus Collection Kit |
| Ferring Pharmaceuticals INC. | $19.75 | 2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $15.86 | 2025 | Givlaari |
| Medtronic, INC. | $14.92 | 2025 | Gi Genius |
| Digestive Care, INC. | $14.51 | 2024 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mo Keovongsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.